Breakdown | |||||
TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
72.92B | 69.90B | 66.41B | 67.82B | 63.65B | 67.84B | Gross Profit |
72.92B | 69.90B | 65.91B | 67.82B | 63.65B | 67.84B | EBIT |
6.45B | 6.66B | 2.16B | 6.36B | 8.52B | 6.93B | EBITDA |
2.94B | 6.66B | 3.92B | 7.97B | 9.74B | 8.46B | Net Income Common Stockholders |
4.50B | 4.43B | 1.58B | 5.28B | 6.86B | 5.41B |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
348.27B | 100.57B | 302.05B | 301.91B | 367.50B | 378.51B | Total Assets |
740.46B | 677.46B | 687.58B | 663.07B | 759.71B | 795.15B | Total Debt |
16.85B | 18.71B | 18.83B | 17.98B | 17.43B | 18.15B | Net Debt |
253.00M | -1.35B | -1.81B | -2.21B | -2.62B | -1.65B | Total Liabilities |
674.08B | 649.75B | 657.33B | 632.95B | 691.96B | 720.33B | Stockholders Equity |
66.14B | 27.45B | 30.02B | 29.88B | 67.48B | 74.56B |
Cash Flow | Free Cash Flow | ||||
16.53B | 14.60B | 13.72B | 13.04B | 12.35B | 11.64B | Operating Cash Flow |
17.05B | 14.60B | 13.72B | 13.04B | 12.35B | 11.64B | Investing Cash Flow |
-12.19B | -11.49B | -10.25B | -2.62B | -11.19B | -18.57B | Financing Cash Flow |
-2.65B | -3.13B | -2.94B | -9.95B | -1.38B | 10.73B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
79 Outperform | $14.21B | 9.61 | 14.68% | 2.06% | 1.69% | 25.54% | |
79 Outperform | $53.66B | 13.01 | 16.08% | 2.77% | 8.77% | 110.90% | |
77 Outperform | $30.61B | 14.10 | 12.82% | 1.95% | -14.78% | 34.80% | |
74 Outperform | $9.91B | 9.77 | 20.47% | 0.82% | 5.41% | 16.60% | |
71 Outperform | $37.38B | 16.71 | 8.04% | 5.01% | 2.47% | 6.88% | |
64 Neutral | $12.83B | 9.78 | 7.78% | 16985.64% | 12.26% | -7.81% | |
64 Neutral | $56.05B | 16.18 | 14.41% | 2.11% | -12.66% | -29.30% |
On May 15, 2025, MetLife, Inc. announced the declaration of quarterly dividends for its preferred stock series. These dividends, payable on June 16, 2025, include $0.35141735 per share for Series A, $351.5625 per share for Series E, and $296.875 per share for Series F, reflecting MetLife’s ongoing commitment to returning value to its shareholders.
The most recent analyst rating on (MET) stock is a Buy with a $85.00 price target. To see the full list of analyst forecasts on Metlife stock, see the MET Stock Forecast page.
On April 30, 2025, MetLife, Inc. announced its financial results for the first quarter of 2025, reporting a 10% increase in net income to $879 million and a 14% rise in premiums, fees, and other revenues to $13.6 billion. The company also authorized a new $3.0 billion share repurchase program and entered into a reinsurance agreement with Talcott Financial Group. The results reflect strong performance across various segments, including a 29% increase in Group Benefits adjusted earnings and significant sales growth in Asia and Latin America. These developments underscore MetLife’s robust operational performance and strategic initiatives to enhance shareholder value.
On April 30, 2025, MetLife, Inc. announced an agreement with Talcott Resolution Life Insurance Company to reinsure approximately $10 billion of U.S. retail variable annuity and rider reserves. This transaction is expected to reduce MetLife’s enterprise risk associated with capital markets and significantly lower its retail variable annuity tail risk by reducing account values by approximately 40%. The transaction aligns with MetLife’s strategic priorities and is expected to close in the second half of 2025, subject to regulatory approvals.
On March 27, 2025, David L. Herzog, a director of MetLife, Inc., announced his resignation from the Board, effective May 1, 2025, and his decision not to seek re-election at the 2025 annual shareholders meeting. Herzog’s resignation was not due to any disagreements with the company’s operations, policies, or practices, indicating a smooth transition without internal conflicts.